Europe's largest initiative launches to accelerate therapy development for COVID-19 and future coronavirus threats

The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics of AZD7442.(1) The trial will include up to 48 healthy participants in the UK aged 18 to 55 years and is funded by the